A
Alcista
Alcista · 25%SYK
$404.29
Precio del escenario
$294.660
+1.444 (+0.49%)Al cierre
Loading chart…
- Máximo
- 299.670
- Apertura
- 295.890
- Precio medio ponderado por volumen
- 296.03
- Volumen
- 3.38M
- Capitalización
- 129.73B
- Mínimo
- 293.750
- Importe
- 999.81M
- EV/EBITDA, TTM
- 13.45
Stryker Corporation is a medical technology company. It offers products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Its segments include MedSurg and Neurotechnology and Orthopaedics. Its MedSurg products include surgical equipment, patient and caregiver safety technologies, and navigation systems (Instruments), endoscopic and communications systems (Endoscopy), and patient handling, emergency medical equipment, intensive care disposable products and clinical communication and artificial intelligence-assisted virtual care platform technology (Medical). Neurotechnology includes neurosurgical, neurovascular and craniomaxillofacial implant products. Its Orthopaedics primarily include implants used in total joint replacements, such as hip, knee and shoulder, and others. It offers solutions for venous thromboembolism clot removal without the use of thrombolytic drugs. It is also focused on treating calcified arterial disease.
Análisis de IA of Stryker Corp (SYK)
MantenerStryker Corp is currently priced at $294.66, which is below several analyst price targets, including $316 from BTIG and $375 from Barclays. However, the recent RSI of 78.996 indicates that the stock is overbought, suggesting caution. Additionally, hedge funds are selling, with a 119.77% increase in selling activity over the last quarter, indicating potential negative sentiment. Therefore, while there are positive catalysts such as the FDA clearance of Sonopet 3, the overall market sentiment and insider selling suggest holding rather than buying at this time.
Recomendaciones de analistas (27)
+46.04% de potencial alcista
Comprar
17 Comprar
8 Mantener
2 Vender
Actual: 294.66
Mínimo
390.00
Promedio
430.32
Máximo
465.00
BTIG
Comprar
$316
2026-10-12
BTIG
2026-10-12
Precio objetivo
$316
Comprar
Barclays
Sobreponderar
$375
2026-10-06
Barclays
2026-10-06
Precio objetivo
$375
Sobreponderar
Truist
Mantener
$310
2026-10-06
Truist
2026-10-06
Precio objetivo
$310
Mantener
Stifel
Comprar
$330
2026-09-30
Stifel
2026-09-30
Precio objetivo
$330
Comprar
TD Cowen
Mantener
$298
2026-09-22
TD Cowen
2026-09-22
Precio objetivo
$298
Mantener
Métricas de valoración
El PER previsto actual de Stryker Corp (SYK) es 16.47, frente a su media de 5 años de 25.60.
Escenarios de precio de Alphio AI para SYK
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Ballenas con SYK en cartera
Cronología de eventos
Noticias
5.010-14PRnewswireStryker's Sonopet 3 Receives FDA Clearance
8.510-12FoolASML Leadership Transition and Future Outlook
5.010-06stocktwitsTruist Lowers Stryker's Financial Forecasts
7.010-01PRnewswireStryker Corporation Shares Plunge 8.8% Amid Ongoing Manufacturing Issues
9.510-01FoolIntuitive Surgical Faces Challenges but Analysts Remain Bullish
Preguntas frecuentes sobre SYK, respondidas por Alphio AI
Stryker Corporation is a medical technology company. It offers products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Its segments include MedSurg and Neurotechnology and Orthopaedics. Its MedSurg products include surgical equipment, patient and caregiver safety technologies, and navigation systems (Instruments), endoscopic and communications systems (Endoscopy), and patient handling, emergency medical equipment, intensive care disposable products and clinical communication and artificial intelligence-assisted virtual care platform technology (Medical). Neurotechnology includes neurosurgical, neurovascular and craniomaxillofacial implant products. Its Orthopaedics primarily include implants used in total joint replacements, such as hip, knee and shoulder, and others. It offers solutions for venous thromboembolism clot removal without the use of thrombolytic drugs. It is also focused on treating calcified arterial disease. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).
Stryker Corp is currently priced at $294.66, which is below several analyst price targets, including $316 from BTIG and $375 from Barclays. However, the recent RSI of 78.996 indicates that the stock is overbought, suggesting caution. Additionally, hedge funds are selling, with a 119.77% increase in selling activity over the last quarter, indicating potential negative sentiment. Therefore, while there are positive catalysts such as the FDA clearance of Sonopet 3, the overall market sentiment and insider selling suggest holding rather than buying at this time.
27 analysts cover SYK: 17 rate it Buy, 8 Hold and 2 Sell. The average price target is 430.32.
Comunidad
Más ↗
$PGR $SYK $BMY Many people enter the crypto space chasing quick profits, but real, consistent success is built on knowledge, discipline, and the right guidance. That’s where having a reliable mentor makes all the difference. Craig has played a key role in helping me understand the markets with more clarity and confidence. His approach to trading goes beyond signals, it’s about building structure, managing risk, and staying focused on long-term growth. With his guidance and his YouTube videos, I’ve been able to make smarter decisions, avoid emotional trading, and stay consistent even in volatile conditions. The shift in mindset alone has been a game changer.
Mostrar más
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.